Trial · NCT02374021
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Renal Calculi | Renal and urinary disorders | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Renal Calculi | Renal and urinary disorders | TNF Inhibitor (Etanercept or Adalimumab) | 2 | 79 | 2 |
| serious | Dysphagia | Gastrointestinal disorders | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Dysphagia | Gastrointestinal disorders | TNF Inhibitor (Etanercept or Adalimumab) | 1 | 79 | 1 |
| serious | Myalgia | Musculoskeletal and connective tissue disorders | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Myalgia | Musculoskeletal and connective tissue disorders | TNF Inhibitor (Etanercept or Adalimumab) | 1 | 79 | 1 |
| serious | Myocardial Infarction | Cardiac disorders | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Myocardial Infarction | Cardiac disorders | TNF Inhibitor (Etanercept or Adalimumab) | 1 | 79 | 1 |
| serious | Vomiting | Gastrointestinal disorders | Triple Therapy (MTX+SSZ+HCQ) | 1 | 80 | 1 |
| serious | Vomiting | Gastrointestinal disorders | TNF Inhibitor (Etanercept or Adalimumab) | 0 | 79 | 0 |
| serious | Back Pain | Musculoskeletal and connective tissue disorders | Triple Therapy (MTX+SSZ+HCQ) | 1 | 80 | 1 |
| serious | Back Pain | Musculoskeletal and connective tissue disorders | TNF Inhibitor (Etanercept or Adalimumab) | 0 | 79 | 0 |
| serious | Abdominal Pain | Gastrointestinal disorders | Triple Therapy (MTX+SSZ+HCQ) | 1 | 80 | 1 |
| serious | Abdominal Pain | Gastrointestinal disorders | TNF Inhibitor (Etanercept or Adalimumab) | 0 | 79 | 0 |
| serious | Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Respiratory Failure | Respiratory, thoracic and mediastinal disorders | TNF Inhibitor (Etanercept or Adalimumab) | 1 | 79 | 1 |
| serious | Neoplasms Benign Malignant And Unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Neoplasms Benign Malignant And Unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | TNF Inhibitor (Etanercept or Adalimumab) | 1 | 79 | 1 |
| serious | Urinary Tract Infection | Renal and urinary disorders | Triple Therapy (MTX+SSZ+HCQ) | 0 | 80 | 0 |
| serious | Urinary Tract Infection | Renal and urinary disorders | TNF Inhibitor (Etanercept or Adalimumab) | 1 | 79 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02374021/events